Not really. At least according a study by Wilson et al. 2025 in Science. In 11 studies, we found that participants typically did not enjoy spending 6 to 15 minutes in a room by themselves with nothing to do but think, that they enjoyed doing mundane external activities much more, and that many preferred to…
Moving clinical data management to cloud platforms can carry myriad benefits for healthcare organizations. The post Bringing Clinical Data Management to the Cloud appeared first on MedCity News.
That is the title of my article out today in The Evidence Base. Here is an excerpt: The Centers for Medicare and Medicaid Services (CMS) are now setting drug prices under the Medicare Drug Price Negotiation program. Unlike other health technology assessment (HTA) bodies worldwide, however, CMS will not consider quality-adjusted life years (QALYs) when setting drug…
The path to a sustainable HaH program looks different for regional systems. A smaller, more focused program, designed around their unique needs, can deliver strong clinical and operational value. The post How Can Hospital-at-Home Grow Outside the Nation’s Biggest Health Systems? appeared first on MedCity News.
[Sponsored] Using RWD to understand SDOH factors faced by patients with non-small cell lung cancer paves the way for improving health equity and more effective treatments for more people. The post The Role of RWD in Revolutionizing Clinical Trial Design appeared first on MedCity News.
By KIM BELLARD On the heels of the disastrous floods in Texas, days away from the Hurricane Katrina twenty year anniversary, and with Hurricane Erin almost becoming another Hurricane Sandy, the dedicated employees at FEMA are worried. Very worried. They’ve got a President who repeatedly has called to dismantle the agency, a DHS Secretary who…
Pluto Health launched an AI-driven digital hub that unifies fragmented health data, provides personalized care navigation and integrates clinical research opportunities to help close primary care access gaps. The platform aims to improve care coordination and make research participation more accessible, especially for patients without insurance or a regular primary care provider. The post Duke…
Cemdisiran, a small interfering RNA drug that Regeneron Pharmaceuticals licensed from Alnylam Pharmaceuticals, met the goals of its pivotal test in generalized myasthenia gravis. The rare neuromuscular disease has several new therapies, but analysts see cemdisiran as having advantages over one particular class of drugs. The post Regeneron’s RNA Med for Muscle Disease Meets Trial…
Dreem Health introduced partnerships with Moona Health, DrLullaby and Daybreak. The partnerships aim to improve care for sleep conditions like insomnia and sleep apnea. The post Dreem Health Launches 3 Partnerships to Address Sleep Disorders appeared first on MedCity News.
LB Pharmaceuticals’ planned IPO will fund late-stage clinical development of LB-102, a once-daily pill designed to improve on the old Sanofi schizophrenia drug Solian. The IPO filing follow a corporate restructuring in May that cut the jobs of LB’s chief financial and scientific officers to streamline operations and extend its cash runway. The post With…